Clinical Trials · NCT06379217
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
- Phase
- Phase 1
- Recruitment status
- Active Not Recruiting
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 31
- Start date
- Jul 2024
- Locations
- 9 sites, 5 countries
- Primary endpoint
- Number/extent of lesions with at least a moderate uptake of any of the Radioligand Imaging (RLI)